Evidence map›Paper›PMID 32555515›Full record

ArticleNature medicine2020

Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.

Thomas Powles, Mark Kockx, Alejo Rodriguez-Vida, Ignacio Duran, Simon J Crabb, Michiel S Van Der Heijden, Bernadett Szabados, Albert Font Pous, Gwenaelle Gravis, Urbano Anido Herranz and 15 more

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in Nature medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors.

Thomas PowlesBarts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK. t.powles@qmul.ac.uk.ORCID http://orcid.org/0000-0001-7760-4724
Mark KockxHistogeneX N.V., Wilrijk, Belgium.
Alejo Rodriguez-VidaDepartment of Medical Oncology, Hospital del Mar, Barcelona, Spain.
Ignacio DuranInstituto de Biomedicina de Sevilla, IBiS, Hospital Universitario Virgen del Rocio, CSIC and Universidad de Sevilla, Seville, Spain.
Simon J CrabbSouthampton Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK.ORCID http://orcid.org/0000-0003-3521-9064
Michiel S Van Der HeijdenDepartment of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Bernadett SzabadosBarts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK.
Albert Font PousCatalan Institute of Oncology, Badalona Applied Research Group in Oncology (B.ARGO)-IGTP, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Gwenaelle GravisInstitut Paoli-Calmettes, Marseille, France.
Urbano Anido HerranzDepartment of Medical Oncology, Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain.ORCID http://orcid.org/0000-0003-0376-5642
Andrew ProtheroeDepartment of Medical Oncology, Churchill Hospital, Oxford, UK.ORCID http://orcid.org/0000-0001-9413-0575
Alain RavaudDepartment of Medical Oncology, Hopital Saint-Andre, University of Bordeaux-CHU Bordeaux, Bordeaux, France.
Denis MailletDepartment of Medical Oncology, Hospital Lyon Sud, Lyon, France.
Maria Jose MendezDepartment of Medical Oncology, Reina Sofia University Hospital, Cordoba, Spain.ORCID http://orcid.org/0000-0002-7460-1859
Cristina SuarezVall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain.
Mark LinchDepartment of Medical Oncology, University College London Hospital, London, UK.
Aaron PrendergastBarts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK.ORCID http://orcid.org/0000-0002-9668-6689
Pieter-Jan van DamHistogeneX N.V., Wilrijk, Belgium.ORCID http://orcid.org/0000-0001-9074-8271
Diana StanoevaHistogeneX N.V., Wilrijk, Belgium.
Sofie DaelemansHistogeneX N.V., Wilrijk, Belgium.
Sanjeev MariathasanGenentech, San Francisco, CA, USA.
Joy S TeaGenentech, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-3395-149X
Kelly MousaBarts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK.
Romain Banchereau *Genentech, San Francisco, CA, USA.
Daniel Castellano *Department of Medical Oncology, Hospital 12 de Octubre, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Identifiers

PMID32555515

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.